Innohep (Tinzaparin Sodium)

Tinzaparin sodium enhances the activity of antithrombin III, which in turn inhibits factor Xa and, to a lesser extent, factor IIa (thrombin). This reduces thrombin generation and fibrin clot formation, providing anticoagulant protection against venous thromboembolism.

The dose of Innohep is individualized by the prescribing clinician based on the patient’s weight, renal function, and the specific indication. Dosing regimens are detailed in the product’s prescribing information and should be followed as directed by a qualified healthcare professional.

Safety of tinzaparin sodium in pregnancy or lactation has not been definitively established. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the Innohep product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Compared with unfractionated heparin, tinzaparin offers more predictable pharmacokinetics, once‑daily subcutaneous dosing, and a lower risk of heparin‑induced thrombocytopenia. Relative to direct oral anticoagulants, it requires injection but provides a reversible anticoagulant effect and is often preferred in patients with severe renal impairment.

Innohep should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and sterility.

Innohep is administered by subcutaneous injection, typically into the abdominal wall or thigh. The injection site should be rotated to minimize local reactions, and aseptic technique must be observed for each dose.

The most serious risks include major bleeding events such as gastrointestinal or intracranial hemorrhage, and heparin‑induced thrombocytopenia (HIT), an immune‑mediated reaction that can paradoxically increase clot formation. Prompt medical evaluation is essential if these occur.

Innohep is contraindicated in patients with a known hypersensitivity to tinzaparin or other heparins, a history of heparin‑induced thrombocytopenia, active major bleeding, or severe uncontrolled hypertension. Clinicians should also avoid use in patients with recent spinal or epidural procedures unless the benefits outweigh the risks.